Neurowyzr raises additional US$2.1M in Seed Funding co-led by Jungle Ventures and Peak XV’s Surge 

SINGAPORE, August 24, 2023Neurowyzr, a pioneering healthtech company specialising in enhancing brain health and developing state-of-the-art technologies to mitigate early brain decline, has raised an additional US$2.1M in an oversubscribed seed round. 

 

The round, jointly led by Jungle Ventures and Peak XV’s Surge (formerly Sequoia India and Southeast Asia), with participation from various angel investors*, brings the total amount raised by the company to US$3.3M. The latest round of capital will be used to accelerate the company’s product development and embark on its next phase of regional expansion across Southeast Asia and India. 

Neurowyzr is developing solutions to address existing gaps in neurology and brain health, at a time when dementia and mental health conditions are rising at an alarming rate. It is projected that by 2050, 152 million people globally will suffer from Alzheimer’s Disease – a more than 2X increase from 2019. One in four is at risk of having a stroke in their lifetime, and one in eight  lives with a mental health disorder. 

In line with the World Health Organisation’s (WHO) call for further research into clinical tools for measuring brain health, Neurowyzr has a unique focus on early brain decline when detection and intervention will have an impact in preventing deterioration. Its first product is an online gamified digital neuroscience assessment called the Digital Brain Function Screen (DBFS), which significantly reduces the time and dollar burden of traditional cognitive testing. 

Since launch, the Neurowyzr team has worked to enable greater patient access to DBFS across key markets. In Singapore, it can be found in a growing number of health screening centres, GP clinics, community care, and specialist centres, including Parkway Shenton, SATA Commhealth, Farrer Park Hospital, MHC Medical Centre (Amara), and O’Joy. The healthcare providers use DBFS in executive health screening, health screening for active agers, Long Covid assessment packages as well as a standalone service. One of India’s largest private hospital chains recently completed a pilot of the DBFS across five locations in India. DBFS has also been registered with the U.S. Food and Drug Administration.

“Brain decline is a potentially debilitating condition that strikes fear in many people, and brings immense cost on families and societies. Neurowyzr aims to address the unmet needs of people to protect their brain health. We are grateful for the trust that our investors have shown in us, and are excited that the partnership will enable us to make brain health accessible and affordable,” said Pang Sze Yunn, Co-Founder and CEO of Neurowyzr. 

 

“Projected numbers tell a stark story for Asia: over the next two decades, more than 66 million individuals could face dementia, while Mild Cognitive Impairment could affect over 400 million.” said Seemant Jauhari, Partner, Healthcare at Jungle Ventures. “Neurowyzr is a direct response to this challenge. By assessing brain and mental health promptly, we’re building a proactive defence against a potential epidemic. This Singapore-born solution carries a global impact.”

Neurowyzr was established by Nav Vij and Pang Sze Yunn in 2019. Its scientific advisory team includes Dr Prem Pillay, Director of the Singapore Brain Nerve Spine Centre, and Professor N Kandiah, Director of the Dementia Research Center, Lee Kong Chian School of Medicine, Nanyang Technological University (NTU). Most recently, the company was selected for the MedTech Innovator Asia Pacific 2023 cohort, the world’s largest industry accelerator.

 

*Angel investors include Khoo Boon Hui, Chairman of SDAX; Ab Gaur, Founder and CEO of MarTech firm Verticurl; and Rob F Jablonski, Commercial Investment Director at Aquivia Pty Ltd. 

Media Contact

Rumaizah (Rumi) Bar
media@neurowyzr.com

About Neurowyzr

Neurowyzr is a Deep Neuroscience and Brain Capital company using the latest discoveries in neuroscience to optimise corporate and population brain health and performance. Built by neuroscientists and powered by advanced analytics and AI, Neurowyzr offers a digital platform and software as a service to unlock the potential of individuals and organisations. Neurowyzr has supported leading organisations in Asia in growing their brain capital to build stronger, more resilient and innovative teams. 

To find out more about Neurowyzr, please visit Neurowyzr.com or follow Neurowyzr on LinkedIn.

 

About Jungle Ventures

Jungle Ventures is a Singapore-based venture capital firm focused on early to growth-stage investments in Southeast Asia and India, with a focus on building long-lasting businesses. Jungle partners with the region’s most exciting founders to build high-growth, capital-efficient technology businesses, and supports their growth from seed to unicorn to IPO. Our portfolio includes regional and global category leaders like Kredivo, Moglix, Pomelo, Livspace, Builder.ai, Sociolla, and more.

Find out more at www.jungle.vc, or follow us on LinkedIn, Twitter, YouTube, or Instagram

 

About Peak XV

Peak XV (formerly Sequoia Capital India & SEA) is a leading venture capital and growth investing firm investing across India, Southeast Asia and beyond. Peak XV (pronounced Peak Fifteen) was the name used for Mount Everest before it was called that. It embodies everything we believe about building long-lasting businesses that stand tall and inspire greatness. 

Over the last 17 years of our operations in the region, Peak XV has grown to manage over USD 9 billion in capital across 13 funds and invested in over 400 companies.

To know more, please visit: www.peakxv.com

 

About Surge 

Surge is Peak XV Partners’ rapid-scale up program. Surge combines up to USD 3 Mn of seed capital with company-building workshops, a global curriculum and support from a community of exceptional mentors and founders. The program’s goal is to supercharge early-stage startups in India and Southeast Asia and give founders an unfair advantage, right out of the gate. For more information on Surge, visit www.surgeahead.com

 

Media Contact 

Redhill, on behalf of Jungle Ventures
Joseph Ng|
joseph@redhill.asia
+65 8121 1665

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Neurowyzr and Allium Healthcare Announce a first-of-its-kind Partnership for Brain Health for Active Agers

Originally posted on https://www.globenewswire.com/news-release/2022/09/28/2523982/0/en/Neurowyzr-and-Allium-Healthcare-Announce-a-first-of-its-kind-Partnership-for-Brain-Health-for-Active-Agers.html

  • Active Agers in Singapore to access innovative and cost-effective brain health assessments and therapy

SINGAPORE, Sept. 28, 2022 (Via GLOBE NEWSWIRE) — Neurowyzr, the Singapore Deep Neuroscience and Brain Capital company with a vision to optimize population and corporate brain health and performance using neuroscience-based digital solutions, announces a partnership with Allium Healthcare to jointly develop brain health programs to help Active Agers screen, monitor, prevent and improve brain health.

Allium will be the first Intermediate and Long-Term care (ILTC) provider in Asia-Pacific to provide Active Ageing programs focused on the brain, using Neurowyzr’s Digital Brain Function Screen and future brain health solutions. For a start, Allium will provide Neurowyzr’s Digital Brain Function Screen that enables early detection of cognitive decline to its residents, day care participants, and members of the community. The digital and gamified solution only takes 14-16 mins to complete and can be completed on a phone or browser. Users will receive a report upon completion that Allium healthcare staff will discuss with their patient in-depth.

Neuroscience studies show that from the age of 30, nearly 10% of people already begin to experience a brain health problem called Mild Cognitive Impairment (MCI). The proportion increases to 25% among people aged 50, and 40% at 60 years1. As such, the World Health Organisation and leading clinical neuroscientists have recommended brain cognitive screening for all adults as part of routine healthcare screening. Early recognition can prevent and reduce the disability of brain health problems that are associated with cognitive decline, stroke, Long Covid brain damage, Parkinson’s disease and dementia. This has the potential to enable prevention, early recognition and treatment of brain health problems that affect millions of people in the Asia Pacific.

Allium will work with Neurowyzr to design therapy options for those detected to have conditions such as Mild Cognitive Decline. Studies such as the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) have shown that therapy for those at risk of cognitive decline is useful in rolling back the condition. Therapy can include computerised cognitive training, diet, aerobic exercise, strength training, improved management of vascular and metabolic conditions. Allium plans to introduce such therapy packages to Singapore, and also study its effectiveness.

Neurowyzr will also work with Allium to roll out future digital neuroscience solutions such as Digital Brain Health Diagnostics and Digital Therapy.

Bernie Poh, CEO, Allium Healthcare commented, “Allium Healthcare works with leading and innovative teams to transform our vision for the finest of hospitality and healthcare into a reality. We are constantly innovating to expand our services to the community. With Singapore’s increasing focus on preventative care, we are excited to leverage new technologies to help Singaporeans on their healthy ageing journeys. This partnership with Neurowyzr increases Allium’s capability to focus on brain health.”

Pang Sze Yunn, CEO, Neurowyzr, commented, “Our partnership with Allium enables Neurowyzr to address the problem of the early cognitive decline among the population. Not only will the population be able to access affordable cognitive screening, there will be more opportunities for them to find therapy options to reverse the decline. We are excited to work with an innovative new partner that is committed to finding solutions to a major societal problem.”

 

Media Contact

Adrienne Chin
adrienne@neurowyzr.com

About Neurowyzr
Neurowyzr is a Deep Neuroscience and Brain Capital company using the latest discoveries in neuroscience to optimize corporate and population brain health and performance. Built by neuroscientists and powered by advanced analytics and AI, Neurowyzr offers a digital platform and software as a service to unlock the potential of individuals and organizations. Neurowyzr has supported leading organisations in Asia in growing their brain capital to build stronger, more resilient and innovative teams. To find out more about Neurowyzr, please visit Neurowyzr.com or follow Neurowyzr on LinkedIn.

Adeline Thia
Thia.Adeline@alliumhealthcare.com

About Allium Healthcare
The Allium Healthcare model benefits from 20 years of experience as a private operator of nursing homes. In Australia, Allium Healthcare co-owns Opal HeaIthcare, one of the largest and leading specialist aged care provider with 8,000 beds in 84 facilities across four states. Allium Care Suites, Singapore’s first premium residential care home on Venus Drive, presents exclusively single and companion suites, bringing together the finest of hospitality and healthcare in skilled nursing, rehabilitative and respite care. Inspired by wellness, defined by personalised care, a team of nurses, allied health professionals and Care Concierges deliver rewarding ages care experiences across residential care, day care, home care and care support services. Discover more at alliumhealthcare.com

___________________________________

1 Eric Braverman, M.D., Cognitive Decline of Aging: Important Neuroendocrinological Predictors of Early Cognitive Decline in A Clinical Setting 

 

 

 

 

 

 

 

Neurowyzr and Parkway Shenton Medical Group Announce a first-of-its-kind Partnership for Digital Brain Health Screening

  • Patients in Singapore are the first in the APAC region to access rapid, fully digitised, cost-effective brain health cognitive assessments

Singapore, May 19, 2022 – Neurowyzr, the Singapore Brain Capital company with a vision to optimize population and corporate brain health and performance using neuroscience-based digital solutions, announces a partnership with Parkway Shenton to provide its patients with digital brain health screening and monitoring tools. Parkway Shenton is the first primary healthcare provider in the Asia Pacific to provide digital brain screening and monitoring using Neurowyzr’s proprietary Digital Brain Function Scan. This has the potential to enable earlier recognition of brain health problems that affect millions of people in the Asia Pacific. Early recognition can prevent and reduce the disability of brain health problems that are associated with cognitive decline, stroke, Long Covid brain damage, Parkinson’s disease and dementia.

For the first time, Singaporeans and residents have access to a digital neuroscience tool through a primary care provider that enables early detection of cognitive decline. Quick, affordable and available through an online portal after being prescribed by a physician,  people no longer need to spend thousands of dollars and several days visiting a specialist clinic to understand the health of their brain.

The World Health Organisation and leading clinical neuroscientists recommend brain cognitive screening for all adults as part of routine healthcare screening. Neuroscience studies show that from the age of 30, nearly 10% of people already begin to experience a brain health problem called Mild Cognitive Impairment (MCI). The proportion increases to 25% among people aged 50, and 40% at 60 years1. People that are at higher risk of brain health problems such as MCI include those with undetected and untreated or poorly- controlled chronic Non-Communicable Diseases (NCD) such as hypertension, diabetes, obesity, metabolic syndrome, high cholesterol, and high lipids. It also includes those who appear healthy but have early liver, kidney, lung and heart failure or dysfunction. This is a major reason to include digital brain health screening as a component of general health screening. It allows users to have a comprehensive picture of their brain and body health, and enables personalised recommendations to be made.

With Neurowyzr’s medical-grade Digital Brain Function Scan that is registered with the Singapore Health Services Authority, patients use any connected device (such as a mobile phone, iPad, laptop or PC) and a browser to complete an assessment within minutes. They receive a report upon completion that the prescribing physician will discuss with their patient in-depth. The ease of the tool significantly reduces the time and dollar burden of traditional cognitive testing that is done in-person with pen and paper that can cost up to several thousand dollars and many hours of physician and patient time.

The Digital Brain Function Scan allows populations to be proactive and preventative when it comes to maintaining the health of their brains. It aims to enable early intervention for brain conditions before severe and irreversible problems arise.

Dr Edwin Chng, Medical Director, Parkway Shenton, commented, “We are constantly expanding our service offerings to patients and leveraging new technologies to bring greater convenience and quality of care to the community. This partnership with Neurowyzr gives Parkway Shenton the unique capability to promote brain health and help our patients play an active role in identifying and preventing problems with cognition.”

Pang Sze Yunn, CEO, Neurowyzr, commented, “Our partnership with Parkway Shenton is an important step in the right direction of recognizing and preventing early cognitive decline. The sooner healthcare providers can intervene when cognitive issues arise, the better the outcomes are for the population. With the increasing medical, social and economic burden of chronic Non-Communicable Diseases, governments and organisations should be paying closer attention to the brain health of citizens and employees. We are excited to work with a new partner who recognises this, and look forward to signing with other likeminded organisations in the months ahead.”

1 Eric Braverman, M.D., Cognitive Decline of Aging: Important Neuroendocrinological Predictors of Early Cognitive Decline in A Clinical Setting

Ends

Media Contact

Hannah Crowe / Jia Rong Chew

Spurwing Communications
Neurowyzr@spurwingcomms.com


About Neurowyzr

Neurowyzr is a brain capital company using the latest thinking in neuroscience to optimize employee brain health and performance. Built by neuroscientists and powered by advanced analytics and AI, Neurowyzr offers a digital platform and software as a service to unlock the potential of individuals and organizations. Neurowyzr has supported leading organisations in Asia in growing their brain capital to build stronger, more resilient and innovative teams. To find out more about Neurowyzr, please visit Neurowyzr.com or follow Neurowyzr on LinkedIn.

About Parkway Shenton

Parkway Shenton is the leading primary healthcare provider in Singapore, with a network of panel general practitioner (GP) clinics and specialists, in-house clinics at corporate clients’ premises, Executive Health Screening as well as Accident and Emergency Departments/24-hour clinics. Through its chain of facilities that are conveniently located island-wide, Parkway Shenton provides a comprehensive range of healthcare services to patients of all ages. Parkway Shenton’s large pool of family physicians are well-qualified in family medicine and management of chronic diseases to provide cost-effective and patient-centric care. It is committed to delivering quality patient care and promoting health and wellness, to help its corporate clients and the general public lead healthier, fuller lives. Parkway Shenton is part of IHH Healthcare, one of the world’s largest healthcare groups with some of the best-known providers of private healthcare in Asia including Acibadem (Turkey), Parkway Group Singapore, Gleneagles Hospitals (Singapore, India, Hong Kong, China), Mount Elizabeth hospitals (Singapore), Fortis hospitals (India), Prince Court Hospital and Pantai Hospital(Malaysia). For more information, please go to www.parkwayshenton.com.

Neurowyzr Announces Strategic Collaboration With Singapore National Employers Federation on Brain Capital Education and Consultancy Services

Singapore, April 11, 2022 – Today, Neurowyzr, the Singapore brain capital company with a vision to optimize employee brain health and performance, announced a strategic collaboration with the Singapore National Employers Federation (SNEF) on brain capital education and consultancy services. A first in Singapore to focus on corporate brain health, the collaboration aims to empower SNEF members to grow their organisational brain capital for the benefit of their employees and organization.

Under the terms of the collaboration, Neurowyzr will provide SNEF corporate members with training programs on various topics within the sphere of workplace brain health, such as the Neuroscience of Leadership, and Brain Capital Ambassador training for managers. Neurowyzr will also work closely with SNEF on providing expert consultancy services to SNEF members to build a happy, resilient and innovative local workforce.

Stephen Yee, Deputy Executive Director of SNEF, commented, “Covid 19 has placed tremendous strain on Singapore companies and workers. We have seen how mental health issues can negatively affect employee performance. SNEF recognizes the importance of approaching brain health holistically, to cover both cognitive and mental health. We are excited to work in partnership with Neurowyzr to provide training and brain health expertise to employers. We want to help Singapore employers build long-term strategies to grow organizational brain capital so that they can innovate and thrive.”

Pang Sze Yunn, CEO, Neurowyzr, commented, “As the Singapore economy becomes more knowledge intensive and complex, there has never been a more pressing time for employers to consider how their workforce can operate at peak brain performance. By objectively measuring brain capabilities and supporting employees to enhance their brain health using a digital platform and software as a service, we will help SNEF member companies unlock individual and organization potential using neuroscience.” 

Ends

Media Contact

Hannah Crowe / Jia Rong Chew

Spurwing Communications
Neurowyzr@spurwingcomms.com


About Neurowyzr

Neurowyzr is a brain capital company using the latest thinking in neuroscience to optimize employee brain health and performance. Built by neuroscientists and powered by advanced analytics and AI, Neurowyzr offers a digital platform and software as a service to unlock the potential of individuals and organizations. Neurowyzr has supported leading organisations in Asia in growing their brain capital to build stronger, more resilient and innovative teams. To find out more about Neurowyzr, please visit Neurowyzr.com or follow Neurowyzr on LinkedIn.

About SNEF 

The Singapore National Employers Federation (SNEF) is a trade union of employers. Our mission is to advance tripartism and enhance labour market flexibility to enable employers to implement responsible employment practices for sustainable growth. SNEF has a membership of over 3,300 companies with a combined workforce of over 800,000. For more information, please visit www.snef.org.sg